CBUS Strangle Strategy
CBUS (Cibus, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
CBUS (Cibus, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $61.9M, a beta of 1.65 versus the broader market, a 52-week range of 1.09-4.191, average daily share volume of 419K, a public-listing history dating back to 2017, approximately 118 full-time employees. These structural characteristics shape how CBUS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.65 indicates CBUS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on CBUS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current CBUS snapshot
As of June 29, 2026, spot at $1.40, ATM IV 22.30%, IV rank 1.23%, expected move 6.39%. The strangle on CBUS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on CBUS specifically: CBUS IV at 22.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a CBUS strangle, with a market-implied 1-standard-deviation move of approximately 6.39% (roughly $0.09 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CBUS expiries trade a higher absolute premium for lower per-day decay. Position sizing on CBUS should anchor to the underlying notional of $1.40 per share and to the trader's directional view on CBUS stock.
CBUS strangle setup
The CBUS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CBUS near $1.40, the first option leg uses a $1.47 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CBUS chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CBUS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.47 | N/A |
| Buy 1 | Put | $1.33 | N/A |
CBUS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
CBUS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on CBUS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on CBUS
Strangles on CBUS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CBUS chain.
CBUS thesis for this strangle
The market-implied 1-standard-deviation range for CBUS extends from approximately $1.31 on the downside to $1.49 on the upside. A CBUS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CBUS IV rank near 1.23% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CBUS at 22.30%. As a Healthcare name, CBUS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CBUS-specific events.
CBUS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CBUS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CBUS alongside the broader basket even when CBUS-specific fundamentals are unchanged. Always rebuild the position from current CBUS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on CBUS?
- A strangle on CBUS is the strangle strategy applied to CBUS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CBUS stock trading near $1.40, the strikes shown on this page are snapped to the nearest listed CBUS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CBUS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CBUS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 22.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CBUS strangle?
- The breakeven for the CBUS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CBUS market-implied 1-standard-deviation expected move is approximately 6.39%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on CBUS?
- Strangles on CBUS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CBUS chain.
- How does current CBUS implied volatility affect this strangle?
- CBUS ATM IV is at 22.30% with IV rank near 1.23%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.